The MEDLINE and Cochrane databases were searched for randomized controlled trials examining the efficacy of SGLT2-i on the treatment of NAFLD/NASH in patients with T2DM. Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.